Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
  • C08G77/04—Polysiloxanes
  • C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
  • C08G77/24—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen halogen-containing groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
  • A61K9/0051—Ocular inserts, ocular implants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7007—Drug-containing films, membranes or sheets
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
  • C08L83/04—Polysiloxanes
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
  • C08G77/04—Polysiloxanes
  • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
  • C08G77/04—Polysiloxanes
  • C08G77/20—Polysiloxanes containing silicon bound to unsaturated aliphatic groups
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
  • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
  • C08G77/70—Siloxanes defined by use of the MDTQ nomenclature

Definitions

• the present invention relates to copolymers useful in the manufacture of matrix controlled diffusion drug delivery systems. More particularly, the present invention relates to matrix controlled diffusion drug delivery systems produced using one or more fluorinated side-chain siloxane polymers.
• controlled release drug delivery systems include both sustained drug delivery systems designed to deliver a drug for a predetermined period of time, and targeted drug delivery systems designed to deliver a drug to a specific area or organ of the body.
• Sustained and/or targeted controlled release drug delivery systems may vary considerably by mode of drug release within three basic drug controlled release categories.
• Basic drug controlled release categories include diffusion controlled release, chemical erosion controlled release and solvent activation controlled release.
• a drug In a diffusion controlled release drug delivery system, a drug is surrounded by an inert barrier and diffuses from an inner reservoir, or a drug is dispersed throughout a polymer and diffuses from the polymer matrix.
• a chemical erosion controlled release drug delivery system a drug is uniformly distributed throughout a biodegradable polymer. The biodegradable polymer is designed to degrade as a result of hydrolysis to then uniformly release the drug.
• a drug is immobilized on polymers within a drug delivery system. Upon solvent activation, the solvent sensitive polymer degrades or swells to release the drug.
• controlled release drug delivery systems to date do not provide a means by which one may manipulate and control drug delivery systems' drug release rate for specific drugs over a broad range of drugs.
• Novel matrix controlled diffusion drug delivery systems of the present invention produced from the polymerization of one or more fluorinated side- chain siloxane monomers, allow for manipulation and control of drug release rates depending on the drug to be delivered, the location of delivery, the purpose of delivery and/or the therapeutic requirements of the individual patient.
• Novel monomers useful in the production of the subject matrix controlled diffusion drug delivery systems are methacrylate-capped polydimethylsiloxanes possessing at least one perfluorinated side chain.
• the perfluorinated side chain contains a terminal -CF2-H functionality.
• the -CF2-H functionality of the side chain is extremely versatile for matrix controlled diffusion drug delivery applications.
• the molecular weight and degree of fluoro-substitution may be varied and the fluorosiloxane monomers can be copolymerized with a wide variety of monomers. Such variability allows for the design of materials possessing a wide range of desirable physical characteristics or properties.
• the terminal -CF2-H functionality provides for improved solubility characteristics. Improved solubility characteristics allows for improved solubility of the fluorosiloxane monomer with a wide variety of hydrophilic monomers and drugs containing hydrogen-bonding groups.
• Another object of the present invention is to provide matrix controlled diffusion drug delivery systems that allow for manipulation and control of drug release rates.
• Another object of the present invention is to provide matrix controlled diffusion drug delivery systems that allow for manipulation and control of drug release rates depending on the drug to be delivered.
• Another object of the present invention is to provide matrix controlled diffusion drug delivery systems that allow for manipulation and control of drug release rates depending on the location of delivery within the body.
• Another object of the present invention is to provide matrix controlled diffusion drug delivery systems that allow for manipulation and control of drug release rates depending on the purpose of drug delivery.
• Still another object of the present invention is to provide matrix controlled diffusion drug delivery systems that allow for manipulation and control of drug release rates depending on the therapeutic requirements of the individual patient.
• the present invention relates to novel fluorosiloxane monomers useful in the manufacture of novel matrix controlled diffusion drug delivery systems.
• the subject matrix controlled diffusion drug delivery systems allow for manipulation and control of drug release rates, which may be based on the drug to be delivered, the location of delivery, the purpose of delivery and/or the therapeutic requirements of the individual patient.
• novel fluorosiloxane monomers of the present invention are methacrylate-capped polydimethylsiloxanes possessing at least one perfluorinated side chain.
• the perfluorinated side chain contains a terminal -CF2-H functionality that is extremely versatile for drug delivery applications.
• the fluorosiloxane monomers of the present invention are generally represented by Formula 1 below:
• Ri groups may be the same or different selected from the group consisting of C 1 -7 alkyl such as for example but not limited to methyl, propyl or butyl but preferably methyl for improved biocompatability, and C 6 - ⁇ o aryl such as for example but not limited to phenyl;
• the R 2 group is a C ⁇ - 7 alkylene such as for example but not limited to methylene, ethylene or heptylene but preferably propylene;
• x is a natural number less than 26;
• p and q may be the same or different natural numbers less than 100 and z is a natural number less than 11.
• the desired rate of drug release may be determined based on the drug to be delivered, the location of delivery, the purpose of delivery and/or the therapeutic requirements of the individual patient.
• the hydrophobic/hydrophilic balance of characteristics dictates the solubility of the drug, and is a primary factor controlling the rate of drug release.
• the polar -CF2-H tail may be used to hydrogen bond with drugs containing polar groups to decrease the rate of drug release.
• Pharmaceutically active agents or drugs useful in the matrix controlled diffusion drug delivery system of the present invention include for example but are not limited to anti-glaucoma agents such as for example but not limited to the beta blockers timolol maleate, betaxolol and metipranolol, mitotics such as for example but not limited to pilocarpine, acetylcholine chloride, isofluorophate, demacarium bromide, echothiophateiodide, phospholine iodide, carbachol and physostigimine, epinephrine and salts such as for example but not limited to dipivefrin hydrochloride, dichlorphenamide, acetazolamide and methazolamide, anti-cataract and anti-diabetic retinopathy agents such as for example but not limited to the aldose reductase inhibitors tolrestat, lisinopril, enalapril and statil, thiol cross-linking
• Other pharmaceutical agents or drugs include anticholinergics, anticoagulants, antifibrinolytics, antihistamines, antimalarials, antitoxins, chelating agents, hormones, immunosuppressives, thrombolytics, vitamins, salts, desensitizers, prostaglandins, amino acids, metabolites and antiallergenics.
• compositions or drugs of particular interest include hydrocortisone (5-20 mcg/l as plasma level), gentamycin (6-10 mcg/ml in
• acetylsalicylic acid trifluorothymidine, interferon ( , ⁇ and ⁇ ), immune modulators such as for example but not limited to lymphokines and monokines and growth factors.
• Monomers useful for copolymerization with the fluorinated side-chain siloxane monomers of the present invention and one or more pharmaceutically active agents include for example but are not limited to methyl methacrylate, N,N-dimethylacrylamide, acrylamide, N- methylacrylamide, 2-hydroxyethyl methacrylate, hydroxyethoxyethyl methacrylate, hydroxydiethoxyethyl methacrylate, methoxyethyl methacrylate, methoxyethoxyethyl methacrylate, methoxydiethoxyethyl methacrylate, poly(ethylene glycol) methacrylate, methoxy-poly(ethylene glycol) methacrylate, methacrylic acid, sodium methacrylate, glycerol methacrylate, hydroxypropyl methacrylate, N-vinylpyrrolidione and hydroxybutyl methacrylate.
• EXAMPLE 2 Synthesis of methacrylate end-capped poly (25 mole percent (3-(2,2,3,3,4,4,5,5,-octafluoropentoxy)propyl methyl siloxane)- co-(75 mole percent dimethylsiloxane)
• the resulting solution was placed on a rotoevaporator to remove tetrahydrofuran and dioxane.
• the resultant crude product was diluted with 300 mL of a 20 percent methylene chloride in pentane solution and passed through a 15 gram column of silica gel using a fifty percent solution of methylene chloride in pentane as eluant.
• the collected solution was again placed on the rotoevaporator to remove solvent and the resultant clear oil was placed under vacuum ( ⁇ 0.1 mm Hg) at 50 Celsius for four hours.
• a film was cast using 70 parts of a methacrylate end-capped DP 100 polydimethylsiloxane containing 25 mole percent of the octafluoropropyloxy side-chain, 30 parts of dimethyl acrylamide, 0.5 percent Darocur 1173 (Ciba-Geigy, Basel, Switzerland) and 5 percent by weight of the drug Fluocinolone Acetonide (FA).
• the cure conditions consisted of a two hour ultraviolet irradiation.
• the film was extracted in isopropanol for 24 hours, air dried and then hydrated in a borate buffered saline.
• the resultant film possessed a modulus of 170 g/mm , a tear of 3 g/mm and a water content of 30.0 percent by weight.
• a film was cast using 30 parts of a methacrylate end-capped DP 100 polydimethylsiloxane containing 25 mole percent of the octafluoropropyloxy side-chain, 70 parts of dimethyl acrylamide, 0.5 percent Darocur 1173 and 5 percent by weight of the drug FA.
• the cure conditions consisted of a two hour ultraviolet irradiation.
• the film was extracted in isopropanol for 24 hours followed by a vacuum dry to remove the isopropanol.
• a 10 mm disc of film from each Example 3 and Example 4 was prepared and mounted to a Kontes diffusion cell between a solution of pH 4 acetate buffer.
• the film from Example 3 is hereinafter referred to as Sample 1 and the film from Example 4 is hereinafter referred to as Sample 2.
• the rate of drug release was monitored by ultraviolet (UV) techniques at 34° Celsius.
• the best results to date were for films of Sample 2 consisting of 30 parts of the methacrylate end-capped fluorosiloxane (DP 100, 25 mole percent fluoro side- chain), 70 parts of methyl methacrylate and 5 percent FA.
• Table 1 and Chart 1 below show the release characteristics of Series 1 and Series 2, which are duplicates of Sample 2, monitored over a period of 1200 hours. For each series tested, a zero-order linear relationship was established shortly after the initial drug release. Based on this relationship, a constant drug release of 800 days (Series 1 ) and 1000 days (Series 2) should occur, assuming this linear relationship is maintained.
• Matrix controlled diffusion drug delivery systems of the present invention may be manufactured in any shape or size suitable for the intended purpose for which they are intended to be used.
• the subject matrix controlled diffusion drug delivery system would preferably be no larger in size than 3 mm 2 .
• Matrix controlled diffusion drug delivery systems of the present invention may be used in a broad range of therapeutic applications.
• the subject controlled release drug delivery system is used by implantation within the interior portion of an eye.
• the subject matrix controlled diffusion drug delivery system may likewise be used in accordance with other surgical procedures known to those skilled in the field of ophthalmology.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Polymers & Plastics (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Inorganic Chemistry (AREA)
• Ophthalmology & Optometry (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=29999052

Family Applications (1)

Country Status (17)

Cited By (1)

Families Citing this family (12)

Citations (3)

Family Cites Families (11)

• 2002
  • 2002-06-19 US US10/175,716 patent/US20040043067A1/en not_active Abandoned
• 2003
  • 2003-06-16 RU RU2005100840/04A patent/RU2307667C2/ru not_active IP Right Cessation
  • 2003-06-16 WO PCT/US2003/019026 patent/WO2004000288A1/en not_active Ceased
  • 2003-06-16 AU AU2003238247A patent/AU2003238247A1/en not_active Abandoned
  • 2003-06-16 PL PL03375000A patent/PL375000A1/xx not_active Application Discontinuation
  • 2003-06-16 CN CN038144662A patent/CN1662227A/zh active Pending
  • 2003-06-16 ES ES03737141T patent/ES2261947T3/es not_active Expired - Lifetime
  • 2003-06-16 BR BR0311963-7A patent/BR0311963A/pt not_active IP Right Cessation
  • 2003-06-16 UA UAA200500490A patent/UA80433C2/uk unknown
  • 2003-06-16 JP JP2004515837A patent/JP2005530842A/ja active Pending
  • 2003-06-16 DE DE60306379T patent/DE60306379T2/de not_active Expired - Fee Related
  • 2003-06-16 MX MXPA04012897A patent/MXPA04012897A/es active IP Right Grant
  • 2003-06-16 CZ CZ20050037A patent/CZ200537A3/cs unknown
  • 2003-06-16 CA CA002489987A patent/CA2489987A1/en not_active Abandoned
  • 2003-06-16 EP EP03737141A patent/EP1515705B1/en not_active Expired - Lifetime
  • 2003-06-18 TW TW092116547A patent/TW200404569A/zh unknown
• 2004
  • 2004-12-09 ZA ZA200409979A patent/ZA200409979B/en unknown

Patent Citations (3)

Also Published As

Similar Documents

Legal Events